Research programme: autologous T-cell therapy - Iovance Biotherapeutics

Drug Profile

Research programme: autologous T-cell therapy - Iovance Biotherapeutics

Alternative Names: HPV TIL

Latest Information Update: 18 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Institute (USA); National Institutes of Health (USA)
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Iovance Biotherapeutics; MedImmune; National Cancer Institute (USA)
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bladder cancer; Breast cancer; Human papillomavirus infections; Lung cancer; Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 11 May 2018 RXi Pharmaceuticals and Iovance Biotherapeutics agree to co-develop sd-rxRNA® therapeutics and TIL autologous cell therapy for Cancer
  • 24 Aug 2017 Iovance Biotherapeutics and H.Lee Moffitt Cancer Center plans to initiate a phase I trial of combination of tumour-infiltrating lymphocytes and nivolumab (Opdivo®) in Non-small cell lung cancer in December 2017 (Iovance Biotherapeutics pipeline, August 2017)
  • 27 Jun 2017 Lion Biotechnologies is now called Iovance Biotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top